Literature DB >> 31017115

Omalizumab in An 8-Year-Old Boy With Diabetes Mellitus and Refractory Chronic Spontaneous Urticaria.

M Jesenak1, M Ciljakova1, M Janickova2, P Banovcin1.   

Abstract

Entities:  

Keywords:  Autoimmunity; Children; Chronic spontaneous urticaria; Omalizumab

Mesh：

Substances：

Year:  2019        PMID： 31017115     DOI： 10.18176/jiaci.0351

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN： 1018-9068            Impact factor:   4.333


× No keyword cloud information.
  3 in total

Review 1.  An Overview of Off-Label Use of Humanized Monoclonal Antibodies in Paediatrics.

Authors:  Roberto Bernardini; Gaia Toschi Vespasiani; Arianna Giannetti
Journal:  Medicina (Kaunas)       Date:  2022-04-29       Impact factor: 2.948

Review 2.  Management of Pediatric Chronic Spontaneous Urticaria: A Review of Current Evidence and Guidelines.

Authors:  Jasmine Chang; Leila Cattelan; Moshe Ben-Shoshan; Michelle Le; Elena Netchiporouk
Journal:  J Asthma Allergy       Date:  2021-03-09

3.  Case Report: Safety and Efficacy of Omalizumab in a 13-Year-Old Patient With Chronic Spontaneous Urticaria and Type 1 Diabetes.

Authors:  Paolo Del Barba; Federica Del Tedesco; Giulio Frontino; Maria Pia Guarneri; Riccardo Bonfanti; Graziano Barera
Journal:  Front Immunol       Date:  2022-04-12       Impact factor: 8.786
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.